UK Prix Galien shortlist announced
pharmafile | May 30, 2012 | News story | Business Services, Medical Communications, Research and Development, Sales and Marketing | Bayer, Janssen, Xarelto, awards, prix galien
The UK award for the most innovative new drug has been moved a step closer with the release of a shortlist in the running for this prestigious prize.
The UK Prix Galien, which is held every two years and celebrates innovative new drugs, has shortlisted products that were launched or granted a new indication in the UK between 1 January 2010 and 31 March 2012.
12 medicines have made the shortlist, which will return to the House of Commons on 26 September.
These drugs are:
- Amgen’s Xgeva (denosumab) for skeletal-related events in adults with bone metastases from solid tumours
- AstraZeneca’s Brilique (ticagrelor) for atherothrombotic events in adult patients with Acute Coronary Syndromes
- Bayer’s Xarelto (rivaroxaban) for deep vein thrombosis, prevention or recurrent DVT and pulmonary embolism
- BMS’ Yervoy (ipilimumab) for advanced melanoma
- Janssen’s Xeplion (paliperidone palmitate) for schizophrenia
- Janssen’s Zytiga (abiraterone) for metastatic castration resistant prostate cancer
- Janssen’s Incivo (telaprevir) for chronic hepatitis C
- Novartis’ Gilenya (fingolimod) for remitting relapsing multiple sclerosis
- Roche’s Zelboraf (vemurafenib) for BRAF positive melanoma
- Shire’s Resolor (prucalopride) for chronic constipation in women
- MSD’s Victrelis (boceprevir) for chronic hepatitis C
- Takeda UK’s Mepact (mifamurtide) for osteosarcoma (Nominated for the Orphan Drug Award).
Karen Westaway, joint chief executive at WG Consulting, which owns UK Prix Galien franchise, said: “The challenge for the UK pharmaceutical industry is to demonstrate that its medicines truly add value, and can help the NHS meet its quality and productivity goals.”
She said that the ethos of Prix Galien is very much aligned with the aspirations of the government’s QIPP agenda, which is looking to make £20 billion in savings across the NHS by 2015.
It also dovetails with the government’s Innovation Health and Wealth Report, she added, which was published in December.
This has been warmly welcomed by the industry and aims to increase access to new medicines whilst also supporting the pharma industry working in the UK.
Westaway added: “It provides the perfect platform for the UK industry to promote its position as world leaders in pharmaceutical research and development.”
NICE chairman Professor Sir Michael Rawlins leads the Prix Galien’s judging panel.
His team also includes experts such as Professor Dame Carol Black, Professor Parveen Kumar, Professor Gordon Duff and the current national cancer director, Professor Sir Michael Richards.
At the 2010 awards Bayer’s anticoagulant Xarelto went home with the top honour, with GSK’s Cervarix and Sanofi Pasteur MSD’s Gardasil cervical cancer vaccines the joint winners for the 2008 prize.
Ben Adams
Related Content
Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …
Winners announced for 2025 PM Society Awards
The pharma marketing and healthcare communications industry gathered for the 39th PM Society Awards on …
Third application for Orion’s prostate cancer drug submitted by partner Bayer
Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application …
